•
EN
ENLV
Enlivex Therapeutics Ltd. Ordinary Shares
polygon--
Price Chart
Market Cap
232.87M
Volume
342.49K
52W High
$2.10
52W Low
$0.66
Open
$0.97
Prev Close
$0.98
Day Range
0.97 - 1.07
About Enlivex Therapeutics Ltd. Ordinary Shares
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Latest News
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
GlobeNewswire Inc.•Aug 18
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetraâ„¢ in Patients with Osteoarthritis
GlobeNewswire Inc.•Oct 30
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
GlobeNewswire Inc.•Jun 17
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
GlobeNewswire Inc.•May 29
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
GlobeNewswire Inc.•May 28
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
GlobeNewswire Inc.•Apr 16
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
Zacks Investment Research•Apr 15
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Benzinga•Apr 12